CHRS logo

Coherus Oncology, Inc.

CHRS
Healthcare|Biotechnology|US
$0.77
+0.02 (+2.82%)
Tangible Book / Share
$0.10
Cash / Share
$0.68
Financing Filings (last 12 months)
6
Shelf registrations / offering prospectuses — latest Aug 28, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (11)

Sep 2027
Est. completion
P2Hepatocellular Carcinoma
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT06679985n=72
Dec 2027
Est. completion
P4Nasopharyngeal Cancer Recurrent
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
NCT06457503n=100
Dec 2027
Est. completion
P1P2Solid Tumor
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
NCT06975293n=107
Dec 2027
Est. completion
P2Squamous Cell Carcinoma
PDT For Induction Therapy For Head And Neck Cancer
NCT07214987n=26
Jan 2028
Est. completion
P1Metastatic Solid Tumor
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
NCT06657144n=154
Feb 2028
Est. completion
P2Sinonasal Cancer
Toripalimab With Chemotherapy for Sinus Cancer
NCT06940180n=20
Dec 2028
Est. completion
P1P2Metastatic Microsatellite Stable Colorectal Carcinoma
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
NCT07281716n=24
Dec 2028
Est. completion
P1P2Metastatic Colorectal Cancer
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
NCT07277322n=24
Apr 2029
Est. completion
P2Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Window of Opportunity in Preserving Laryngeal Function Trial
NCT07423078n=87
Jul 2029
Est. completion
P2Localized Colon Carcinoma
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
NCT07140679n=40
Oct 2030
Est. completion
P2Head and Neck Cancer
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
NCT07209189n=75

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Sep 2026
P1
Study of CHS-114 in Participants With Advanced Solid Tumors
NCT05635643

Recent Press Releases

Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development
Oct 28, 2026 · GlobeNewsWire
Coherus to Participate in Upcoming Investor Conferences
Oct 27, 2026 · GlobeNewsWire
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
Oct 26, 2026 · GlobeNewsWire
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
Oct 14, 2026 · GlobeNewsWire
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
Sep 23, 2026 · GlobeNewsWire
Coherus to Participate in Upcoming Investor Conferences
Aug 31, 2026 · GlobeNewsWire
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
Aug 17, 2026 · GlobeNewsWire

SEC Filings (81)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 29, 20268-KMaterial eventDocumentIndex
Aug 28, 20268-KMaterial eventDocumentIndex
Aug 28, 2026424B5Offering prospectusDocumentIndex
Aug 28, 2026424B3Offering prospectusDocumentIndex
Aug 17, 20268-KMaterial eventDocumentIndex
Aug 17, 20268-KMaterial eventDocumentIndex
Aug 5, 2026S-8Employee stock planDocumentIndex
Aug 5, 202610-QQuarterly reportDocumentIndex
Aug 5, 20268-KMaterial eventDocumentIndex
Jul 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jun 15, 20268-KMaterial eventDocumentIndex
Jun 1, 20268-KMaterial eventDocumentIndex
May 28, 2026DEFA14AProxy / shareholder voteDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 11, 202610-QQuarterly reportDocumentIndex
May 11, 20268-KMaterial eventDocumentIndex
May 11, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 5, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 29, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Apr 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Apr 20, 2026ARSAnnual report to holdersDocumentIndex
Apr 20, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 14, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 9, 2026PRE 14AProxy / shareholder voteDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 9, 202610-KAnnual reportDocumentIndex
Mar 9, 20268-KMaterial eventDocumentIndex
Feb 17, 20268-KMaterial eventDocumentIndex
Feb 13, 2026424B5Offering prospectusDocumentIndex
Feb 12, 2026424B5Offering prospectusDocumentIndex
Feb 5, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 4, 20268-KMaterial eventDocumentIndex
Jan 30, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 23, 20268-KMaterial eventDocumentIndex
Jan 23, 2026424B5Offering prospectusDocumentIndex
Jan 13, 20268-KMaterial eventDocumentIndex
Dec 8, 2025EFFECTDocumentIndex
Nov 13, 2025S-3Shelf registrationDocumentIndex
Nov 13, 2025S-8Employee stock planDocumentIndex
Nov 13, 20258-KMaterial eventDocumentIndex